Thymosin Alpha-1 Fails to Restore T Cell Counts in COVID-19 Patients
Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients.
Background
The SARS-CoV-2 virus, responsible for COVID-19, often causes significant immune system disruption, including lymphopenia—a reduction in white blood cells, particularly CD4+ and CD8+ T lymphocytes (key immune cells that fight infections). Thymosin Alpha-1 (TA1) is an immunomodulatory peptide known for enhancing T cell function and maturation, making it a potential candidate for immune restoration. However, its specific efficacy in restoring depleted CD4+ and CD8+ T lymphocyte counts in COVID-19 patients remained an open question.